New therapeutic approaches for equine protozoal myeloencephalitis: Pharmacokinetics of diclazuril sodium salts in horses

Levent Dirikolu, Wojciech Karpiesiuk, Andreas F. Lehner, Charlie Hughes, William E. Woods, John D. Harkins, Jeff Boyles, Alfonza Atkinson, David E. Granstrom, Thomas Tobin

Research output: Contribution to journalArticlepeer-review

Abstract

Diclazuril, a triazine-based antiprotozoal agent, may have clinical application in the treatment of equine protozoal myeloencephalitis (EPM). Diclazuril was rapidly absorbed, with peak plasma concentrations occurring at 8 to 24 hours after oral-mucosal administration of diclazuril sodium salt. The mean oral bioavailability of diclazuril as Clinacox was 9.5% relative to oral-mucosal administration of diclazuril sodium salt; diclazuril in dimethyl sulfoxide administered orally was 50% less bioavailable than with oral-mucosal administration of diclazuril sodium salt. Diclazuril sodium salt has the potential to be used as a feed additive for the treatment and prophylaxis of EPM and various other apicomplexan-mediated diseases.

Original languageEnglish (US)
Pages (from-to)52-63+72
JournalVeterinary Therapeutics
Volume7
Issue number1
StatePublished - Mar 1 2006

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'New therapeutic approaches for equine protozoal myeloencephalitis: Pharmacokinetics of diclazuril sodium salts in horses'. Together they form a unique fingerprint.

Cite this